About: Maraviroc

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Maraviroc Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B5830-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5831-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5832-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5833-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/group	approved (en) investigational (en)
http://linked.open...drugbank/halfLife	14-18 hours (en)
http://linked.open...ugbank/indication	For treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. (en)
sameAs	Maraviroc Maraviroc
Title	Maraviroc (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB04835/identifier/chemspider/2273675 http://linked.opendata.cz/resource/drugbank/drug/DB04835/identifier/drugbank/DB04835 http://linked.opendata.cz/resource/drugbank/drug/DB04835/identifier/guide-to-pharmacology/806 http://linked.opendata.cz/resource/drugbank/drug/DB04835/identifier/iuphar/806 http://linked.opendata.cz/resource/drugbank/drug/DB04835/identifier/national-drug-code-directory/0069-0807-60 http://linked.opendata.cz/resource/drugbank/drug/DB04835/identifier/pubchem-compound/3002977 http://linked.opendata.cz/resource/drugbank/drug/DB04835/identifier/pubchem-substance/46508040 http://linked.opendata.cz/resource/drugbank/drug/DB04835/identifier/pharmgkb/PA164768835 http://linked.opendata.cz/resource/drugbank/drug/DB04835/identifier/wikipedia/Maraviroc
http://linked.open...mechanismOfAction	Maraviroc is an entry inhibitor and works by blocking HIV from entering human cells. Specifically maraviroc is a selective, slowly reversible, small molecule antagonist of the interaction between human CCR5 and HIV-1 gp120. Maraviroc selectively binds to the human chemokine receptor CCR5 present on the membrane of CD4 cells (T-cells), preventing the interaction of HIV-1 gp120 and CCR5 necessary for CCR5-tropic HIV-1 to enter cells. (en)
http://linked.open...drugbank/packager	Sandoz Lake Erie Medical and Surgical Supply Pfizer Inc. Physicians Total Care Inc. ViiV Healthcare ULC
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/2350073 http://linked.opendata.cz/resource/drugbank/patent/2408909 http://linked.opendata.cz/resource/drugbank/patent/6586430 http://linked.opendata.cz/resource/drugbank/patent/7368460
http://linked.open...umeOfDistribution	* 194 L (en)
http://linked.open...nk/proteinBinding	Approximately 76% bound to human plasma proteins, with moderate affinity for albumin and alpha-1 acid glycoprotein. (en)
http://linked.open...ynthesisReference	"DrugSyn.org":http://www.drugsyn.org/Maraviroc.htm (en)
foaf:page	http://www.drugs.com/cdi/maraviroc.html http://www.rxlist.com/cgi/generic/selzentry.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B5838-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B583E-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B583D-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B583A-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B583B-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B583C-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B5836-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B5834-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5837-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B5835-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Maraviroc
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B5844-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B5845-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B583F-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B5840-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B5842-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B5841-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B5843-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	The absolute oral bioavailability of a 100 mg dose is 23% and is predicted to be 33% at 300 mg. Coadministration of a 300mg tablet with a high fat breakfast reduced maraviroc Cmax and AUC by 33% in healthy volunteers. (en)
http://linked.open.../affectedOrganism	Human Immunodeficiency Virus (en)
http://linked.open...casRegistryNumber	376348-65-1 (en)
http://linked.open...gbank/containedIn	Selzentry 150 mg tablet Apo-Olanzapine 10 mg Tablet
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B584A-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B584C-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B584D-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B5849-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B5848-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B584B-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B5839-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B5846-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B5847-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 117 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software